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a b s t r a c t
Two hundred and seventy four asymptomatic Ghanaian school-children aged 5 to 17 years were screened
for malaria parasites by examination of blood ﬁlms. One hundred and ﬁfty ﬁve microscopically-positive
individuals were treated with dihydroartemisinin-piperaquine and followed for 3 weeks. Retrospective
species-speciﬁc PCR of all 274 screened samples identiﬁed an additional 60 children with sub-patent par-
asitaemia, and a substantial proportion of co-infections with Plasmodium malariae, Plasmodium ovale curt-
isi and Plasmodium ovale wallikeri. One hundred individuals harboured at least one non-falciparum
parasite species. Using standard double-read microscopy, the 21-day efﬁcacy of treatment against Plas-
modium falciparum was 91.4% among the 117 children seen at all 5 visits. Using nested PCR to test 152
visit 5 blood samples, 22 were found to be parasite-positive. Twenty individuals harboured P. falciparum,
four harboured P. ovale spp. and two P. malariae, with four of these 22 isolates being mixed species infec-
tions. The persistent detection of low density Plasmodium sp. infections following antimalarial treatment
suggests these may be a hitherto unrecognised obstacle to malaria elimination.
 2013 Australian Society for Parasitology. Published by Elsevier Ltd.
1. Introduction
Studies of malaria in sub-Saharan Africa have been focused on a
single parasite species, Plasmodium falciparum, because of its pre-
dominance among clinical cases, and its association with severe
disease and mortality. Three other species are widespread in Africa
but generally thought to be uncommon among clinical malaria
cases: Plasmodium malariae, Plasmodium ovale curtisi and Plasmo-
dium ovale wallikeri (Collins and Jeffery, 2007; Sutherland et al.,
2010). However recent cross-sectional population-based studies
in Malawi, Uganda, Equatorial Guinea and Angola, using PCR for
parasite detection and species discrimination, have shown that
these three species are found in between 1% and 17% of tested indi-
viduals, regardless of whether malaria symptoms were present
(Bruce et al., 2008; Oguike et al., 2011; Fançony et al., 2012). In
each of these studies, the majority of these occurrences were as
co-infections with P. falciparum, and we therefore surmise that,
in Africa, P. malariae and P. ovale spp. will frequently encounter
control measures and case management strategies designed specif-
ically for falciparum malaria.
Infections with non-falciparum malaria parasites have been
adequately treated with chloroquine for many decades (Lalloo
et al., 2007). However, in most African settings, species-level diag-
nosis is not available for people suffering from malaria (or sus-
pected malaria), and so virtually all patients are treated for P.
falciparum and are thus likely to receive artemisinin-combination
therapy (ACT) where these drugs are available. Unfortunately,
there are few in vivo data available to indicate how well non-falci-
parum species respond to ACT. Clinical trials commonly exclude
mixed infections at enrolment and molecular characterisation of
treated parasite isolates is not commonplace. Partially based on
evidence for good efﬁcacy of ACT against Plasmodium vivax in Asia
(Kolaczinski et al., 2007; Douglas et al., 2010), it is expected that
ACT will be very effective against P. malariae, P. o. curtisi and P. o.
wallikeri. Recent evidence from Gabon would support this view
(Mombo-Ngoma et al., 2012). As current research is now illuminat-
ing the moderately high prevalence of these species across Africa, it
is important to assess the response of non-falciparum parasites to
commonly used antimalarial drugs, and in particular to ACT.
As part of a study of P. falciparum gametocyte carriage and
associated antibody responses, asymptomatic Ghanaian school
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children with parasitaemia were enrolled in a longitudinal study.
Microscopy-conﬁrmed P. falciparum malaria infections were trea-
ted with a full course of the ACT dihydroartemisinin-piperaquine
(DP). As an ancillary analysis, we tested for the presence of all
Plasmodium species by PCR, both prior to and 3 weeks after treat-
ment, and estimated drug efﬁcacy against sub-patent parasitaemia.
2. Materials & methods
2.1. Study area
The study was conducted during the months of October–
December 2010, in Pokukrom in the Ahafo Ano South District of
the Ashanti region, which lies in the tropical rainforest ecological
zone of Ghana. The mean monthly temperature ranges between
18 and 38 C and the average rainfall in the neighbouring area of
Kintampo is 1250 mm per annum, occurring mainly between
May and October each year (Owusu-Agyei et al., 2009). The district
is considered endemic for malaria and a parasite carriage rate of
65% has previously been recorded (H. Tagbor, unpublished data).
Transmission of malaria in this area is perennial but peaks during
the rainy season. Malaria is predominantly caused by P. falciparum
(Asante et al., 2011) and no published studies have looked at the
prevalence of the other malaria species in the district. The main
vectors are Anopheles gambiae and Anopheles funestus; no current
estimates of entomologic inoculation rate are available for Ahafo
Ano District, but in Kintampo this is estimated to be 250 infectious
bites per year (Owusu-Agyei et al., 2009). Laboratory support and
microscopy facilities were provided at the Kwame Nkrumah Uni-
versity of Science and Technology (KNUST), Department of Biology,
Kumasi. The study protocols were approved by the Ghana Health
Service Ethics Committee (proposal # GHS-ERC-08/7/10) and the
Ethics Committee of the London School of Hygiene and Tropical
Medicine (proposal # 5775). Individual informed consent was ob-
tained from the children and their parents/guardians before enrol-
ment. Meetings were also held in the community and schools to
explain the objectives of the study and to seek the consent of the
community leaders and education authorities.
2.2. Participants and sample collection
Asymptomatic school children of Pokukrom Methodist primary
between the ages of 5 and 17 years were screened for asexual ma-
laria parasites in ﬁnger-prick peripheral blood. For each sample a
rapid immunochromatographic point-of-care test (RDT) for anti-
genaemia was carried out (Malaria Pf rapid test, Shenyang LTH
Technology Development Company, Beijing, China), blood smears
made for microscopy, and approximately 10–50 lL of blood spot-
ted directly from the child’s ﬁnger onto Whatman grade 3 ﬁlter pa-
per (Whatman, Maidstone, UK). Microscope slides were dried in
the ﬁeld and taken to KNUST for staining and examination. Filter
paper blood spots were allowed to dry for 2–3 min and then trans-
ported in separate unsealed plastic bags together with a desiccant.
Upon reaching the lab the ﬁlter papers were dried in an air-
conditioned room for 24 h before freezing at 80 C until
processing for parasite DNA extraction was carried out.
All children were clinically examined by a trained nurse to en-
sure that no child had symptoms suggestive of malaria. Any child
with a positive RDT and symptoms suggestive of malaria at visit
1 was immediately treated with DP as described below; these
symptomatic cases were not enrolled and do not contribute to
the current study on asymptomatic parasite carriage. The medical
history and other information of each child were recorded in a case
report form. School children who participated in the screening pro-
cess were monitored daily for malaria symptoms by a nurse for one
week at school. Children were advised to seek medical treatment at
a designated health facility if they were to experience any symp-
toms related to malaria outside of school hours. The slides were
read at KNUST by experienced microscopists and at the second vis-
it of the study team to the participating school, 7 days after the ﬁrst
visit when samples were taken, all asymptomatic children with
conﬁrmed parasitaemia (sexual or asexual or both) at the time of
visit 1 were enrolled. Inclusion criteria were: a recorded axillary
body temperature of less than 37.5 C, no history of fever in the
previous 48 h and microscopically conﬁrmed parasitaemia caused
by P. falciparum with or without the presence of other Plasmodium
species. All enrollees were treated with a standard regimen of DP,
comprising 3 daily doses each of 1–3 tablets, depending on the
weight and age, of P-ALAXIN (Bliss GVS Pharma LTD, Mumbai, In-
dia), containing 40 mg dihydroartemisinin (DHA) and 320 mg
piperaquine phosphate per tablet. The study medicines were
sourced from the Komfo Anokye Teaching Hospital in Kumasi. A
sample of two tablets was tested for quality using an established
method (Ioset and Kaur, 2009), and found to contain 98% of the sta-
ted amount of DHA and 101% of the stated amount of piperaquine.
The medicinal quality of this product was therefore within the ac-
cepted tolerance limits of 95–105%, as set by the US Pharmacopeia
(2012).
Each daily dose of the ﬁxed-combination was administered un-
der observation in the classroom, or if falling on a weekend, in the
child’s home, under supervision by teachers or study staff mem-
bers. Children with symptomatic malaria or with evidence of any
other chronic or acute illness were excluded from the study. En-
rolled children were followed up for repeat ﬁnger-prick blood sam-
ples weekly for 4 weeks after the ﬁrst blood sample was taken; as
treatment was given on the second visit, each child was thus seen
three further times after treatment. During this period the partici-
pants had access to free anti-malarial treatment and clinical care if
required. The longitudinal study was designed to permit testing for
plasma antibodies against P. falciparum gametocyte antigens in
children with asymptomatic P. falciparum infections cleared by
DP. Parasitological ﬁndings reported here were ancillary to the
main study.
2.3. Microscopy or examination of blood smears
Thick and thin blood smears were stained with 10% Giemsa
after ﬁxing thin smears with methanol. Asexual parasite densities
were determined by counting against 200 leukocytes, and convert-
ing to parasites per lL by assuming a standard leukocyte count of
8000/lL (Greenwood and Armstrong, 1991). At least 100 high
power ﬁelds were examined before a thick smear was declared
negative. Each slide was read independently by two experienced
readers, and the geometric mean reading of the two replicates used
for analysis. A third reader read the slide in cases where the para-
site density estimates of the ﬁrst two readers differed bymore than
10%. Sexual parasite rate and density were determined by counting
against 500 leukocytes and converted to parasites per lL as for
asexual parasites (Drakeley et al., 2004).
2.4. Species identiﬁcation by nested PCR
DNA was extracted from ﬁlter paper blood spots from visits 1
and 5 respectively in a 96-well plate using Chelex resin as
previously described (Oguike et al., 2011). Plasmodium species
were identiﬁed by nested PCR ampliﬁcation of the small sub-unit
ribosomal genes as previously described (Snounou et al., 1993)
with the following second round PCR primers and amplicon sizes:
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P. falciparum primers: rfal1 + rfal2 205 bp product
P. malariae primers: rmal1 + rmal2 144 bp product
P. vivax primers: rviv1 + rviv2 120 bp product
P. ovale primers: PovaFWD + RVScommon 375 bp product
Newly designed P. ovale spp. primers were deployed because
the original pair of primers described by Snounou et al. (1993)
do not amplify P. o. wallikeri.
PovaFWD: 50-CTGTTCTTTGCATTCCTTATGC-30
RVS common: 50-GTATCTGATCGTCTTCACTCCC-30
For the second round ampliﬁcation, 1 ll of ﬁrst round PCR prod-
uct was ampliﬁed in a 20 ll reaction containing 10 ll of HotStar
Taq master mix (Qiagen, UK) and 0.2 lM of each primer. PCR prod-
ucts were resolved on 2% agarose gels.
2.5. Discrimination between P. o. curtisi and P. o. wallikeri
P. o. curtisi and P. o. wallikeriwere distinguished from each other by
nested PCR ampliﬁcation of the gene coding for tryptophan-rich anti-
gen, and fractionation on agarose gels, or by direct sequencing of pog3p
and porbp2 amplicons as previously described (Oguike et al., 2011).
2.6. Statistical analysis
Associations between binary variables were tested using the
chi-squared statistic, with Fisher’s exact correction for comparisons
in which any expected value was less than 6. Estimation of
summary statistics and all tests of association were performed in
STATA software (Stata 12.0, Statacorp, Texas, US).
3. Results
3.1. Parasite carriage by microscopy
Single-read microscopy of all 274 children immediately fol-
lowing screening identiﬁed 165 with positive blood ﬁlms (geo-
metric mean density 1.87 parasites lL1 peripheral blood,
range 0–428 lL1). Consent for inclusion in the longitudinal
study was obtained from parents/guardians for 155 of these chil-
dren. Deﬁnitive double-read microscopy carried out after com-
pletion of the study found an additional 16 children positive
for P. falciparum trophozoites that had not been enrolled in the
longitudinal study. Twenty-one of the enrolled children (13.6%)
carried patent gametocytes of P. falciparum, 14 of whom carried
concurrent asexual parasites. Further, the microscopists reported
that the blood ﬁlms of a small number of children with visible P.
falciparum trophozoites also harboured blood-stage parasites of
either P. malariae (24 children) or P. ovale spp. (3 children)
(Fig. 1A).
At visit 2 (7 days after the ﬁrst visit), DP treatment was given
under observation to all 155 enrolled participants and a further
blood ﬁlm and ﬁlter paper collected. Double-read microscopy
found that 55 of the 155 enrolled children no longer harboured
patent asexual parasites, and that two of seven children who at vis-
it 1 had circulating gametocytes only now harboured detectable
asexual parasites of P. falciparum. These data show that a number
of children in the study harboured ﬂuctuating parasite densities
very close to the limit of detection of microscopy, and hence para-
site detection was often discordant between the two visits, despite
Fig. 1. Prevalence of Plasmodium spp. by microscopy (Panel A) and species-speciﬁc rRNA SSU nested PCR (Panel B). All children in the longitudinal study were identiﬁed as
positive for P. falciparum at visit 1. Some children missed follow-up on visits 2–5 due to absence from school on the day. Only parasitological results from children in the
longitudinal study are shown. DP: dihydroartemisinin-piperaquine.
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no treatment having been administered at the time of taking the
second blood sample.
3.2. Species-speciﬁc PCR to detect parasite carriage prior to treatment
As expected, retrospective PCR analysis of DNA extracted from
all 274 blood spots collected at visit 1 found 45 additional sub-pat-
ent P. falciparum infections. It was also shown that a high propor-
tion of enrolled individuals were found to carry non-falciparum
parasite species. A further 15 children previously parasite-negative
by microscopy harboured P. malariae, and 8 were PCR positive for
P. ovale spp., many children harbouring multi-species infections
(Table 1). In total, 215 individuals out of 270 evaluable PCR tests
(79.6%) were parasite positive for at least one species. Whereas
115 children among the 215 who were parasite positive were
found to harbour P. falciparum alone, eight individuals were in-
fected only with non-falciparum species, and 92 with P. falciparum
and at least one of the other species. These ﬁndings are summa-
rised using a simple binary species code in Table 1. The overall
prevalence of P. malariae in all children tested was 28% (76 chil-
dren), and that of P. ovale spp. was 16.3% (44 children). Taking
the median age of 10 years as a cut-off, evidence was found that
PCR-detected carriage was more common in the older group for
both P. falciparum (OR: 2.21; 95% CI: 1.18–4.25; P = 0.0082) and
P. malariae (OR: 2.07; 95% CI: 1.17–3.69; P = 0.0077), but not for
P. ovale spp. (OR: 0.860; 95% CI: 0.422–1.73; P = 0.651). Further,
the occurrence of either or both non-falciparum species at visit 1
was much more likely in children who were also positive for P. fal-
ciparum by PCR (odds ratio OR: 5.50; 95% CI: 2.43–14.0; P < 0.001).
This relationship with P. falciparum carriage was also seen for P.
malariae or P. ovale spp. when considered separately (OR: 7.87;
95% CI: 2.73–30.8; P < 0.001 and OR: 2.69; 95% CI: 0.990–9.14;
P = 0.040, respectively). Thus 67 of the 155 children treated with
DP in this study and followed up also harboured PCR-conﬁrmed
non-falciparum malaria infections, which were thus inadvertently
exposed to one of the currently recommended ACT regimens.
P. o. curtisi and P. o. wallikeri are indistinguishable by micros-
copy, and so PCR ampliﬁcation of the potra and pog3p genes was
performed to discriminate which species were present in the 44
children identiﬁed by nested PCR as carrying P. ovale spp. (Oguike
et al., 2011). Electrophoretic fractionation of potra ampliﬁcation
products, or direct sequencing of pog3p amplicons was able to
identify P. o. curtisi in 27 individuals and P. o. wallikeri in 7 individ-
uals. (In the remaining 10 children there was insufﬁcient material
to make a species-level identiﬁcation.) Two children appeared to
harbour both species by the potra assay. As individuals with both
species present simultaneously have only recently been described
(Fançony et al., 2012; Fuehrer et al., 2012), we investigated these
two children in more detail, repeating the original tests, and using
other discriminatory loci (Sutherland et al., 2010). The presence of
both P. o. curtisi and P. o. wallikeri sequences at each of the loci po-
tra, pog3p, and porbp2 was conﬁrmed in both individuals, as se-
quences identical to those described for both species in previous
studies were found (Sutherland et al., 2010; Oguike et al., 2011).
Thus we conclude that each of these children harboured both par-
asite species that cause ovale malaria, supporting the recent dem-
onstration that these related species are able to infect a single host
simultaneously.
3.3. Parasite carriage following DHA-piperaquine
Of 155 children microscopy positive on visit 1, treated with DP
on visit 2 and followed up, four remained positive for P. falciparum
trophozoites by microscopy at visit 5 (Fig. 1A). Species-speciﬁc PCR
gave four different species codes for these individuals (Table 1):
100, 110, 111 and 001. Thus, in one case, the microscopists identi-
ﬁed P. ovale spp. parasites as a recurrent P. falciparum infection.
Nested PCR testing of all samples at visit 5 identiﬁed 22 parasite
positive individuals, a prevalence of recurrent parasitaemia
3 weeks after treatment of 14.5%. Unexpectedly, in only 16 of these
individuals was P. falciparum the sole parasite species detected by
nested PCR (Table 1; Fig. 1B). Thus post-treatment parasitaemia
with non-falciparum malaria was detected in 6 individuals, and
of these four were positive for this same species prior to treatment,
two children each for P. ovale and P. malariae. The proportion of
post-treatment infections positive for DNA from P. ovale spp. was
18%, which is similar to the baseline proportion of 20.5%. Two of
these were conﬁrmed as P. o. curtisi by genotyping at both potra
and pog3p loci, whereas insufﬁcient material was available to
deﬁnitively identify the remaining two P. ovale spp. infections.
DNA from P. malariae was detected in 13.6% of post-treatment
infections, compared to 35.4% of infections prior to treatment.
4. Discussion
This study examines, in asymptomatic Ghanaian school children,
the effect of ACT against the three less-common parasite species
which infect people in sub-Saharan Africa: P. malariae, P. o. curtisi
and P. o. wallikeri. These species are generally considered sensitive
to standard antimalarial drugs including chloroquine (Collins and
Jeffery, 2007; Mueller et al., 2007), yet we have shown using PCR-
based detection that a small number of these infections recurred
3 weeks after treatment of asymptomatic parasite-positive individ-
uals. As DP is known to provide good post-treatment prophylaxis
(Four ABC Study Group, 2011), this ﬁndingwas unexpected. In addi-
tion, we provide conﬁrmation, using a multi-gene typing approach,
that P. o. curtisi and P. o. wallikeri can be found simultaneously in a
single individual, as two of our school children were found to har-
bour both ovale parasite types prior to treatment. Taking these re-
sults together with recent ﬁndings from Bangladesh and Angola
(Fançony et al., 2012; Fuehrer et al., 2012), the weight of evidence
is now ﬁrmly against our previously stated hypothesis that human
blood groups may restrict P. o. curtisi and P. o. wallikeri to different
subsets of sympatric human communities (Sutherland et al., 2010).
An interesting ﬁnding was that, among the 274 children origi-
nally screened, P. malariae and P. falciparum, but not P. ovale spp.,
were detected signiﬁcantly more often in children 10 years and
over. This is likely to be related to fewer episodes of febrile illness
(whether malaria or not) in the older children and thus less
frequent use of antimalarial drugs. If this suggestion is true, the
absence of such an age relationship for P. ovale spp. can be
Table 1
Mixed parasite species carriage detected by PCR at enrolment and 3 weeks post-
treatment Data on parasite carriage is presented as a binary code for each of the three
species (with all ovale infections considered together), where ‘‘0’’ denotes the absence
of a species, and ‘‘1’’ denotes its presence by nested PCR. Only children with PCR data
indicating the presence of at least one species are shown at each timepoint.
Pf/Pm/Po PCR code Visit 1 (N = 270) Visit 5: 3 weeks post-treatment
(N = 152)
Freq. Percent Freq. Percent
000 55 20.4 130 85.5
001 4 1.5 2 1.3
010 3 1.1 0 0.0
011 1 0.4 0 0.0
100 115 42.6 16 10.5
101 20 7.4 1 0.7
110 53 19.6 2 1.3
111 19 7.0 1 0.7
Total 270 100.0 152 100
Pf: Plasmodium falciparum; Pm: P. malariae; Po: P. ovale spp.
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attributed to the ability of P. o. curtisi and P. o. wallikeri to relapse
from dormant liver-stage hypnozoites once antimalarial drugs
have cleared from the host bloodstream (Nolder, Oguike & Suther-
land, unpublished data). Further, P. malariae and P. ovale spp. were
signiﬁcantly more commonly detected by PCR in individuals that
were also PCR-positive for P. falciparum. Whereas hitherto un-
known biological mechanisms may be responsible for this phe-
nomenon, a simple and parsimonious explanation is that all
three parasites are circulating in the same Anopheles mosquito
populations, and thus children more exposed to P. falciparum infec-
tion because they live near mosquito habitat, have an unscreened
house or do not use a bednet will also be more often exposed to
the other Plasmodium species. Identiﬁcation of Plasmodium species
in blood-fed anophelines from this area would help to test this
explanation. Further detailed studies of the associations between
age, multi-species parasite carriage, quality of housing, exposure
to biting mosquitoes and patterns of community drug use in
African endemic areas are clearly needed.
The presence of PCR-detectable parasitaemia 3 weeks after ACT
treatment in some of the study children is of concern. However,
in vivo antimalarial drug efﬁcacy cannot be meaningfully estimated
from treatment outcomes in asymptomatic infections, and PCR
positivity is not (yet) validated as a primary endpoint for clinical
trials of antimalarial therapy. Bearing in mind these caveats, we
nevertheless expected a higher rate of complete parasite clearance
among the asymptomatic cases of Plasmodium spp. infection in our
study. As piperaquine is considered to have a prophylactic effect
lasting more than 3 weeks (d’Alessandro, 2009; Four ABC Study
Group, 2011), emergent blood-stage infections from recent mos-
quito bites should also have been prevented. The observation that
DNA from non-falciparum parasite species can be detected within
3 weeks of treatment with an effective ACT in school children was
particularly unexpected, suggesting continuing asexual parasita-
emia of P. malariae and P. ovale spp. in these individuals. There
are a few possible alternative hypotheses to explain our ﬁndings
of persistent sub-patent parasitaemia. Firstly, DNA from dead ma-
laria parasites may persist post-treatment, either in circulating sol-
uble form or in phagocytes that have engulfed parasites, and
deliver a ‘‘false-positive’’ signal in diagnostic PCR tests (Sutherland
and Hallett, 2009). However, there is no direct evidence to support
this, and persistent DNA from dead parasites is unlikely to remain
detectable after 3 weeks, particularly with the low starting parasite
densities in our study subjects. A second plausible explanation is
that the DNA we have detected is only from the gametocytes (sex-
ual stages) of these species. It is known for P. falciparum that game-
tocyte carriage after DP treatment is more common than for other
regimens such as artemether-lumefantrine (Four ABC Study Group,
2011), and that gametocytes of this species remain circulating in a
proportion of ACT-treated malaria patients long after apparent
clearance of asexual stages (Targett et al., 2001). Gametocytes of
P. malariae and P. ovale spp. circulate in the peripheral blood
of infected people at the same time as asexual stage parasites,
and it is generally assumed that they have only a short lifespan
in vivo. However, knowledge of the patterns of gametocyte
carriage for these species is mostly drawn from malaria in travel-
lers, experimental infections in naive volunteers and from studies
of therapeutic malaria induced in syphilis patients in the mid
20th century (Garnham, 1966). This knowledge is therefore unli-
kely to accurately reﬂect the actual patterns in endemic country
populations. A full understanding of the effect of treatment on
the gametocytes of P. malariae and P. ovale spp. can only be gained
once new methods of detection for these sexual stages are
developed.
Given that the arguments above may not explain our results,
the apparent ‘‘failure’’ of ACT to clear P. malariae and P. ovale spp.
in Ghanaian school children requires further consideration. P. ovale
spp. are known to relapse from dormant liver-stages analogous to
the hypnozoites of P. vivax and Plasmodium cynomolgi (Garnham,
1948; Shortt and Garnham, 1948) and both ovale species are
known to cause relapse clinical malaria months or years after
exposure to infected mosquitoes (Sutherland et al., 2010). There
is thus reason to think that P. ovale spp. relapses may follow treat-
ment of P. falciparum infections, as is described for P. vivax in Asia
(Douglas et al., 2011). However, given the long half-life of piperaq-
uine (d’Alessandro, 2009; Four ABC Study Group, 2011) and the rel-
atively short period of follow-up in the present study (3 weeks) a
relapse emergence from the liver would have been expected to
encounter reasonable plasma levels of piperaquine and thus fail
to reach detectable levels (even by PCR) in this short time. Thus
there may be some other intrinsic survival mechanism that P. ovale
spp. can deploy to evade drug clearance. P. malariae on the other
hand is thought to lack the ability to relapse from dormant liver
stages (Shortt and Garnham, 1948; Ciuca et al., 1964; Collins and
Jeffery, 2007). The 72 h (quartan) intra-erythrocytic cycle time
may make this species particularly well suited to evading the effect
of most artemisinin regimens, as each dose generates only a short
pulse of active plasma DHA which is very rapidly cleared. P. mala-
riae infections may therefore be more likely to leave a few survi-
vors after each dose of artemisinin is administered. There are
concerns that the current amount of DHA used in the ﬁxed
combination DP as given to children results in under-dosing
(d’Alessandro, 2009; Tarning et al., 2012), and longer dosage regi-
mens of ACT may be required for complete clearance of P. malariae
infections. In addition, this parasite is well known to possess a
capacity for dormancy, lasting decades in some well documented
cases (Vinetz et al., 1998). Although the mechanism or host tissue
reservoirs are unknown, it is plausible that this same ability may
assist in evasion of antimalarial therapy in this species.
Equally of concern is the persistent detection of P. falciparum at
3 weeks in approximately 15% of DP-treated individuals in this
study. By microscopy, 4 individuals were recorded as positive for
P. falciparum asexual parasites 3 weeks after treatment, whereas
PCR identiﬁed 10 individuals positive for this species, some of
which may be carrying only gametocytes. A priori, it could be as-
sumed that asymptomatic infections with P. falciparum, at low par-
asite densities, would be easier to clear with efﬁcacious
antimalarial regimens. On the contrary, we ﬁnd a number of
PCR-detectable infections only 3 weeks after DP. A possible expla-
nation for this is that in chronic, asymptomatic infections malaria
parasites are in a steady-state relationship with the host, and do
not elicit immune responses that are capable of participating in
drug-induced parasite clearance; thus drug efﬁcacy may be par-
tially compromised against such infections. In contrast, symptom-
atic infections are by deﬁnition immunogenic, and thus the
outcome of treatment is the sum effect of drug and both innate
and acquired immune responses (Djimde´ et al., 2003; Diallo
et al., 2007). A potential mechanism for such a phenomenon is
the expression, by parasites in a chronic infection, of surface anti-
gen PfEMP1 variants that have weak adhesive properties and are
poorly immunogenic (Jensen et al., 2004; Bull et al., 2005). This
would explain a relative lack of immune clearance in comparison
to symptomatic infections, but does not explain how these para-
sites evade drug-induced killing.
5. Conclusions
This report raises two areas of concern for programmes seeking
to eliminate malaria in sub-Saharan Africa. Firstly, co-infecting
non-falciparum species were found by PCR to be common in
asymptomatic individuals with patent P. falciparum parasitaemia,
and the deployment of an ACT thought efﬁcacious against all three
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species failed to completely clear P. malariae and P. ovale spp. in
approximately 10% of individuals over 3 weeks of follow-up. The
reason for persistent detection of parasites is unknown. Secondly,
although ACT clearance of asymptomatic P. falciparum infections
was efﬁcacious using a microscopy endpoint, PCR-detectable para-
sites were identiﬁed within 21 days of treatment. The role of the
immune system in assisting drug-induced parasite clearance may
be compromised in chronic low-grade infections of this parasite.
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